Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
Provided By GlobeNewswire
Last update: Nov 4, 2025
Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated Data and Clinical Development Update Expected in Early 2026
Read more at globenewswire.com
